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Abstract
This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) 
of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well 
differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually 
the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20–30% of patients suffering 
from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. 
The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the 
diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video 
capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed histological report is crucial 
for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either 
radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the 
appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA 
treatment, with good expression of somatostatin receptors, the first-line treatment should be radioisotope therapy, while targeted therapies, such 
as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered. 
(Endokrynol Pol 2017; 68 (2): 223–236)
Key words: neuroendocrine neoplasms; guidelines; small intestine; appendix; carcinoid syndrome; somatostatin analogues; PRRT, radioisotope 
therapy; everolimus 
Introduction
Neuroendocrine neoplasms (NEN) of the small intestine 
originate in the midgut, with the small intestine being 
the third most common site of their occurrence, after the 
pancreas and large intestine. From the clinical point of 
view, we distinguish between hormonally active and 
non-active NENs. Hormonally active NENs secrete 
substances that cause the characteristic symptoms 
known as carcinoid syndrome. Most small intestinal 
NENs are well differentiated and grow slowly. Rarely, 
they may be poorly differentiated, with rapid growth 
and a poor prognosis. However, small intestinal NENs 
are often diagnosed in the generalised stage with 
distant metastases. Tumours in this location are very 
rarely part of MEN 1 syndrome [1–4].
Neuroendocrine neoplasms of the end part of the 
small intestine and the appendix are mostly composed 
of EC (enterochromaffin) cells, responsible for serotonin 
production. Certain NENs demonstrate the ability to se-
crete enteroglucagon, glucagon, or other peptides. It is 
believed that ileum NENs are more aggressive than the 
neuroendocrine tumours of the duodenum, tumours of 
the stomach built of ECL (enterochromaffin-like) cells, 
or tumours of the rectum. They demonstrate a higher 
metastatic ability, associated to a lesser degree with the 
size of the tumour [1–3].  
1. Epidemiology
The small intestine, particularly the ileum, is the most 
common site of NENs in the human body. Small in-
testinal NENs occur equally often in male and female 
patients; they affect all age groups, with the peak in 
the 6th and 7th decades of life. The estimated preva-
lence is 0.32–1.12 per 100,000 of the population per 
year, including malignancy in 0.29 per 100,000. Apart 
from the small intestine, they also affect the appendix 
[3, 5–11]. In post-mortem examinations the reported 
prevalence increases to 1.22% [3, 12]. Tumours originat-
ing from the lower part of the jejunum and the ileum 
constitute 23–38% of all gastro-entero-pancreatic en-
docrine neoplasms, and they are more common than 
endocrine neoplasms of the appendix, also described 
in paediatric patients [3, 13, 14]. Hormonally active 
neuroendocrine neoplasms of the small intestine are 
often multifocal, and in 15% of cases are associated 
with other neoplasms such as gastrointestinal adeno-
carcinoma or breast cancer [3]. 
The term carcinoid is still associated with a certain 
ambiguity. In the past, the term referred to a neu-
roendocrine neoplasm, regardless of the location of 
the primary tumour site or the level of malignancy. 
Later, in Europe, carcinoids were limited to neoplasms 
originating from the midgut, secreting serotonin and 
associated with carcinoid syndrome symptoms. How-
ever, the World Health Organisation (WHO) 2010 
classification of the gastro-entero-pancreatic neuroen-
docrine neoplasms attributed the term carcinoid to G1 
neuroendocrine neoplasms. The Polish Network of 
Neuroendocrine Tumours argues that the term ‘carci-
noid’ should be relinquished, and substituted with the 
name ‘neuroendocrine tumour’ or ‘neuroendocrine 
neoplasm’ [2, 3, 5, 15, 16].
Over the last 30 years, the incidence of neuroen-
docrine neoplasms of the gastrointestinal tract has in-
creased by 720%, and of the small intestine by 460%. In 
this period there has also been an increase in the ileum 
neuroendocrine neoplasm rate within the small intes-
tine, from 52% to 63.6%. This is very important because 
neoplasms are malignant in this area in 58% of cases, 
whereas this group of tumours constitutes no more than 
35% of cases within the whole small intestine. A higher 
prevalence has been observed in African-Americans 
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and in females, compared to Caucasians and males. Al-
though the increase in the diagnosis of gastric and rectal 
NENs can be partially explained by the development of 
endoscopic techniques, such an explanation does not 
apply to the higher incidence of small intestinal NENs 
[2, 3, 5, 17, 18]. According to experts from the Polish 
Network of Neuroendocrine Tumours, endoscopic tests 
of the large intestine, including screening colonoscopy 
(over about a 20 year period) increased the detection of 
small intestinal NENs. The person performing colonos-
copy in most cases assesses not only the large intestine, 
but also the terminal part of the small intestine, where 
small intestinal NENs are found most frequently [19, 20]. 
Most tumours are located in the terminal part of the 
ileum, in close proximity to the ileocaecal valve. They often 
involve metastases to the regional lymph nodes, and then 
to the liver. The prognosis in these cases is usually poor 
and depends on the TNM staging assessment and Ki-67 
grading [3, 16]. The five-year survival rate is 100% for pa-
tients with stages I and II small intestinal NENs, 97.1% for 
patients with stage III, and 84.8% for patients with stage IV. 
Based on the level of tumour differentiation, the five-year 
survival rate is 93.8% for G1, 83% for G2, and 50% for G3 
[3, 21]. Other studies have reported the five-year survival 
rate to be 72% in patients with local tumours, and 55% in 
patients with distant metastases [3, 22]. According to alter-
native European data, the five-year survival rate is 59–74% 
in patients with NENs of the small intestine and appendix 
[3, 9, 23]. Previous observations demonstrated a ten-year 
survival rate of 60% in patients without liver metastases 
at the diagnosis, and 15–25% in metastatic patients. Mul-
tifactorial analyses suggest that tumour metastases to the 
lymph nodes, hepatic involvement, and distant metastases 
outside the abdominal cavity are independently related to 
the survival rates. Moreover, the prognosis may improve 
if the primary tumour is removed [3].
2. Clinical characteristics
2.1. Symptoms of the hormonally active NETs of 
the small intestine — carcinoid syndrome
Carcinoid syndrome occurs in approximately 20–30% 
of patients suffering from small intestinal NETs with 
distant metastases. Carcinoid syndrome comprises 
symptoms resulting from an excessive secretion of 
serotonin and other biologically active compounds 
by the tumour (including kinins, prostaglandins, and 
histamine). Serotonin secreted to the portal venous 
system is metabolised in the liver and does not cause 
any clinical symptoms. The symptoms occur if serotonin 
and other biogenic amines are secreted directly to the 
systemic circulation; therefore, the carcinoid syndrome 
symptoms occur most often with hepatic metastases 
from NETs (approximately 95% of cases) [1,3].
Clinical symptoms of carcinoid syndrome include: 
(a) symptoms affecting the skin (flushing, telangiecta-
sis, pellagra — skin inflammation caused by vitamin 
PP deficiency, resulting from the use of tryptophan 
for excessive serotonin production by the neoplasm); 
(b) symptoms affecting the gastrointestinal tract (secre-
tory diarrhoea, non-specific or colic abdominal pains); 
(c) symptoms affecting the cardiovascular system 
(tricuspid valve disorders, diseases of the pulmo-
nary trunk, rarely mitral valve and aorta disorders); 
(d) symptoms affecting the respiratory system (bron-
chial asthma); and e) symptoms affecting the muscu-
loskeletal system (osteoarticular pains, myopathies) 
[3, 24]. Carcinoid syndrome significantly reduces the 
quality of life in patients with small intestinal NETs [25].
Flushing is one of the main symptoms of carcinoid 
syndrome (60–85% of patients). The flushing that 
accompanies serotonin secreting NETs of the small 
intestine (classical carcinoid syndrome) is pale-pink to 
red, affecting the face and upper chest, and lasting up 
to 30 minutes. Triggering factors include alcohol, spicy 
foods, emotional stress, and medications (serotonin 
reuptake inhibitors). Flushing in the case of foregut 
NETs (atypical form of carcinoid syndrome) is more 
intensive, with a crimson shade, and lasts longer (as 
long as several days) [3, 26].
The main causes of death in patients with carcinoid 
syndrome are heart diseases — referred to as carcinoid 
heart disease (CHD) or Hedinger’s syndrome, which 
may affect 25–50% of patients. CHD is mainly charac-
terised by plaques of fibrous tissue on the valves of the 
right heart, leading to tricuspid valve regurgitation/ 
/stenosis (the most common defect) and stenosis/regur-
gitation of the pulmonary valve. Initially the clinical 
symptoms of CHD are weakly pronounced; later the 
symptoms of right ventricular heart failure progress. 
The prognosis for patients with CHD and severe heart 
failure (NYHA classes III and IV) is unfavourable; the 
median survival rate for patients without cardiosur-
gical treatment is 11 months. The gold standard in 
CHD diagnosis is echocardiography, which should be 
performed in all patients with carcinoid syndrome. 
Possible NET metastases to the pericardium should also 
be considered [3, 27–29].
Carcinoid crisis is a rare, life-threatening complication 
caused by a sudden release of biologically active substanc-
es to the systemic circulation. The symptoms include: 
prolonged skin redness, intense diarrhoea or vomiting, 
wheezing, blood pressure fluctuations, arrhythmia, 
disturbed nervous system function, dehydration, shock, 
acute renal failure, or hypercalcaemia. The crisis may 
occur independently, during infection, or as a result of 
medical procedures: general anaesthesia, endoscopy, tu-
mour biopsy, surgery, embolisation, radioisotope therapy, 
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or chemotherapy [3, 30]. Therefore, it is recommended 
that somatostatin analogues are used in the pre-operative 
period or during surgery on NEN patients [3]. 
2.2. Symptoms of hormonally non-active NENs of 
the small intestine
The clinical picture of hormonally non-active NENs 
of the small intestine relates to the local symptoms. 
Small tumours are usually asymptomatic; they are 
found while identifying the source of metastases, 
or accidentally during colonoscopy in the ileocaecal 
region. Larger tumours, of more than 1 cm, are usu-
ally malignant and metastatic. The most common 
symptoms reported by patients are non-specific and 
include transient abdominal pains and discomfort 
(lasting for years, and often misinterpreted as irritable 
bowel syndrome), weight loss, and weakness. Over 
time, the symptoms worsen and may result in tran-
sient obstructions of the small intestine caused by the 
presence of the tumour mass, or by the desmoplastic 
reaction of the mesentery. Moreover, the desmoplastic 
reaction can impair the blood supply in the intestines, 
in severe cases leading to necrosis. A desmoplastic 
reaction rarely results in retroperitoneal fibrosis or 
hydronephrosis. Severe gastrointestinal bleeding is 
a rare symptom of small intestine NENs [3, 4, 31]. 
2.3. Symptoms of NENs of the appendix (aNENs)
Appendicitis is usually the first manifestation of carci-
noid in this location. Over half of the neuroendocrine 
neoplasms of the appendix are discovered accidentally 
following appendectomy. Most NENs of the appendix 
are diagnosed at the early stages. This contributes to 
a high survival rate in patients with tumours in this 
location, which is particularly visible in children, where 
over 80% of the diagnosed tumours are smaller than 
1 cm. The size of the tumour is of crucial importance for 
the occurrence of metastases: for tumours smaller than 
1 cm in diameter, metastases occur in 2%; for tumours 
of 1–2 cm in diameter, it is 50%; and for tumours larger 
than 2 cm, it is 80–90% of patients [3, 32]. Based on the 
data analysis from the SEER database, 10-year survival 
was observed in 100% of aNEN patients without lymph 
node metastases, and over 90% in metastatic patients, 
regardless of the size of the original tumour [33].  
3. Diagnostics 
3.1. Laboratory diagnostics
In the biochemical diagnostics of NEN of the small 
intestine and appendix, it is useful to determine the 
concentration of chromogranin A (CgA) — a sensitive 
although not highly specific marker (the determination 
and interpretation of results are described in the section on 
general diagnostics of gastro-entero-pancreatic neuroendo-
crine tumours). A significantly increased CgA concentra-
tion may be treated as an indicator of poor prognosis 
[3, 34–36].
The assessment of 5-hydroxyindoleacetic acid 
(5-HIAA) excretion in urine is a sensitive tumour 
indicator, useful for the diagnosis and monitoring 
of disease progression or treatment in patients with 
carcinoid syndrome. The sensitivity and specificity of 
5-HIAA determination in order to confirm carcinoid 
syndrome are 70–100% and 85–90%, respectively [3]. 
The determination of blood serotonin levels is not 
presently recommended in the diagnostics of carcinoid 
syndrome [34, 37].
In the diagnostics and assessment of the severity of 
carcinoid heart disease, the determination of 5-HIAA 
and NT-proBNP (N-terminal-pro-B-type natriuretic 
peptide) may be useful [3, 34, 38].
Tests on the use of new biomarkers indicate that 
molecular tests could be used in the diagnostics and 
monitoring of NENs. Once validated, they would most 
probably be implemented in clinical practice [39, 40].
Minimal consensus statement on biochemical tests:
 — CgA and 5-HIAA in all patients diagnosed with NEN of 
the small intestine before treatment and during monitor-
ing (*evidence level 3);
 — 5-HIAA — in patients with suspected carcinoid syndrome 
(*evidence level 3);
 — NT-proBNP — in the case of carcinoid heart disease 
(*evidence level 4). 
3.2. Imaging and endoscopic diagnostics
3.2.1 Primary tumour location
The diagnostics of small intestine diseases may include 
computed tomography (CT) enterography/enteroclysis 
or magnetic resonance imaging (MRI) enterography/ 
/enteroclysis, which locate the primary focus in the 
small intestine in approximately 90–97% of patients 
[41–43]. For the follow-up concerning small intestine 
diseases, CT or MRI enterography should be applied. 
MRI enteroclysis should be performed in patients with 
a clinically suspected pathology of the small intestine 
and with negative MRI/CT enterography results 
[3, 5, 44, 45].
Ultrasonography (US) is of limited use in detecting 
the primary tumour site. It is a subjective test, where 
the results depend on the quality of the equipment. 
In individual cases a transabdominal US of the small 
intestine, using high frequency probes, may enable the 
detection of the primary tumour site. However, possible 
secondary lesions in the mesentery should be consid-
*evidence level according to OCEBM [109]
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ered, such as enlarged, hypoechogenic lymph nodes, 
or fibrosis/thickening of the mesentery, which may be 
more visible than a small primary tumour site hidden 
in the intestinal wall. It may be of use in the preliminary 
diagnostics of patients with suspected NENs [46].
Endoscopic diagnostics of the small intestine is 
usually undertaken to identify the primary tumour 
site in the case of metastases of unknown origin (often 
significantly larger than the primary tumour), in the 
case of non-specific abdominal symptoms, or to find the 
cause of gastrointestinal bleeding [3, 47]. The common 
use of colonoscopy, including screening colonoscopy, 
enables early detection of small intestinal lesions. The 
direct presentation of a NEN located in the small intes-
tine is possible during a colonoscopy, when the tumour 
protrudes through the ileocaecal valve into the caecum 
lumen (such cases are very rare), but primarily takes 
place during routine assessment of the distal section 
of the small intestine. Colonoscopy is also important 
to exclude a concomitant neoplastic disease, and it 
enables endoscopic treatment [48]. Endoscopic ultra-
sonography (EUS), unlike for other locations of GEP 
NEN lesions, is of no use in the diagnostics of small 
intestine tumours [3].
Video capsule endoscopy (VCE) and balloon or spi-
ral enteroscopy can be used for direct assessment of the 
jejunum and ileum mucosa, but these methods are not 
commonly used. A complete assessment of the small 
intestine is achieved in approximately 80% of patients, 
and the overall diagnostic efficiency of the test is about 
55% [3, 49–53]. VCE sensitivity in the diagnosis of neu-
roendocrine tumours is relatively low, and compared 
to CT enterography is 29–37.5% vs. 50–92% [3, 54]. It 
is worth emphasising that neuroendocrine neoplasms 
of the small intestine, due to secreted growth factors 
resulting in desmoplastic reactions of the mesentery, 
often cause significant narrowing of the intestine, 
which is an absolute contraindication for video capsule 
endoscopy, because of the risk of capsule incarceration 
[55]. Another disadvantage of VCE is the inability to 
locate the tumour precisely [3, 56–58]. Balloon enter-
oscopy or spiral enteroscopy are not associated with 
this shortcoming, but their diagnostic efficiency is not 
very high [3, 59–62]. Enteroscopy enables not only the 
detection of small intestinal lesions, but also of endo-
scopic treatment [63]. 
Radioisotope diagnostics with the use of radioi-
sotope-labelled somatostatin analogues (somatostatin 
receptor imaging, SRI) is a more sensitive method than 
radiological tests. The sensitivity of SRI is approximately 
80% for the identification of the primary tumour site 
[64, 65]. Examinations using positron tracers (e.g. 68Ga) 
are the preferred imaging method, particularly if the 
lesions are < 1 cm [66]. To locate the primary tumour 
site and assess the disease stage, SRI in correlation 
with multiphase CT/MRI is recommended. In the case 
of incomplete surgery of the NEN of the appendix 
or if distant metastases are suspected, SRI should be 
performed [67].
3.2.2. Evaluation of the stage of advancement and 
response to treatment
Multiphase, mostly three-phase, CT or MRI examina-
tions after intravenous administration of the contrast 
agent and filling the intestinal lumen with a negative 
contrast agent, as well as SRI, are methods that enable 
the monitoring of the disease and assessment of the 
response to therapy [p. 79–110]. 
Minimal consensus statement on imaging and endo-
scopic examinations:
To locate the primary tumour site and assess the stage of 
advancement, SRI in correlation with multiphase CT/MRI 
is recommended (*evidence level 3)
 — CT/MRI enterography, CT/MRI enteroclysis, or endo-
scopic techniques may be required to locate the primary 
tumour site (*evidence level 3).
 — Colonoscopy and assessment of the terminal section of the 
ileum to detect the primary lesion and to exclude a concomi-
tant neoplastic disease (colon cancer) (*evidence level 4). 
3.3. Pathomorphological diagnostics
3.3.1. NENs of the small intestine
Neuroendocrine tumours of the small intestine differ 
from other gastro-entero-pancreatic NETs, as they 
originate exclusively from serotonin-producing cells. 
Most are well-differentiated and demonstrate low 
proliferative activity. Therefore, their growth is slow 
and associated with slowly increasing, non-specific 
clinical symptoms. Thus, most of them are diagnosed as 
a regional, advanced disease. The diagnostics of small 
intestine NENs, due to their specific clinical course, is 
frequently based on the assessment of the material from 
a large-core needle biopsy of the tumour (or its hepatic 
metastases), which is often the first clinical symptom, 
or examination of the small intestine material removed 
due to obstruction, along with the previously undiag-
nosed tumour.  
3.3.1.1. Diagnostic algorithm
Histopathological reporting is still the basis for the dia-
gnosis of neuroendocrine tumours, as well as for other 
solid neoplasms. Histopathological type and stage of 
advancement according to the current standards enable 
the application of therapeutic management according 
to the current state of knowledge [4].
*evidence level according to OCEBM [109]
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Macroscopic assessment of small intestinal NENs 
in post-surgical material
Procedures included in the Standards of the Pol-
ish Society of Pathologists should be followed during 
preparation of the post-surgical material from the 
removed small intestinal tumour [68].
1. The tumour location, considering the length of the 
intestinal section obtained for examination, the 
tumour relation to the intestine resection margins, 
and the width of the removed intestinal mesentery.
2. Tumour size, preferably in three dimensions. In the 
case of numerous lesions, their size, mutual relation, 
and resection margins should be provided. Relation 
of the tumour(s) to the layers of the intestinal and 
mesenteric wall.
3. Presence and size of the mesenteric lymph nodes.
4. Other pathological lesions in the assessed material.
Microscopic assessment on NENs:
The histopathological assessment is based on the 
WHO 2017 [69] classification and [69] ENETS 2016 
guidelines [4,32] together with the AJCC 8th edition 
from 2017 [70]. As in other sections of the gastroin-
testinal tract, NENs are classified as neuroendocrine 
well-differentiated neoplasms: NETs G1 with Ki-67 
index below 3% and NETs G2 with Ki-67 between 3% 
and 20%, and NEC, which include NETs G3 and neu-
roendocrine carcinomas: large- or small-cell NEC, and 
MiNEN (mixed endocrine non-endocrine neoplasms). 
The diagnostic criteria are discussed in Diagnostic and 
therapeutic guidelines for gastro-entero-pancreatic neu-
roendocrine neoplasms (p. 79–110). Histopathological 
assessment should include:
1. Histopathological type of the NEN according to the 
WHO 2017 classification, completed with Chapter 
2.2 and Table VII.
2. The histological grading (G) according to ENETS/ 
/WHO 2017.
3. Assessment of the immunohistochemical expression 
of neuroendocrine markers: chromogranin A and 
synaptophysin, as well as Ki-67/MIB1 proliferative 
activity (as described below) according to the pro-
cedure described in the general section – obligatory 
[32, 71, 72].
4. Pathomorphological pTNM staging according to 
ENETS and AJCC/UICC — obligatory — Table I. 
Assessment of clinical staging conditional — Table 
II [4].
5. Assessment of other immunohistochemical markers, 
such as NSE, CD56, CDX2, serotonin, somatostatin 
receptors — conditional [4]. 
A minimal histopathological report on small intes-
tinal NEN should include:
 — Histological type of the neoplasm according to the 
WHO classification, considering the division into 
well-differentiated neuroendocrine neoplasms 
(NETs G1 and NETs G2) with Ki-67 index below 
20%, and NETs G3 and neuroendocrine carcinomas 
(NECs) with Ki-67 index above 20% or mixed neo-
plasms (MiNEN).
 — Histological G grading, referring to well-differen-
tiated neoplasms (NETs G1, NETs G2, NETs G3).
 — pTNM histopathological staging according to ENETS 
and AJCC/UICC classifications (it is important to pro-
vide the affiliation of the classification in each case);
 — Assessment of surgical margins.
 — The histopathological diagnosis of NEN must be 
confirmed by immunohistochemical tests assess-
ing the expression of the neuroendocrine markers: 
synaptophysin and chromogranin A, as well as Ki-67 
proliferative activity using the MIB1 antigen. 
Recent TNM UICC 2017 classification [72] divides 
metastases to lymph nodes into N1: metastases pre-
sent in less than 12 lymph nodes, of ≤ 2 cm, and N2: 
metastases present in 12 or more lymph nodes and/or 
presence of a metastases of > 2 cm.
The classification of distant metastases also changes.
Metastases (feature M1) is divided into three groups.
Table I. TNM UICC/AJCC and ENETS classification systems 
for NENs of the small intestine [32, 71, 72]. 
Feature T – 
primary tumour x
Comment
TX The tumour has not been assessed
T0 No evidence of a primary tumour
T1 Tumour invades the lamina propria or submucosa 
and is 
≤ 1 cm
T2 Tumour invades the muscularis propria and/or is 
> 1 cm 
T3 Tumour penetrates the muscularis propria and 
invades the subserosal tissue, without serosal 
invasion
T4 Tumour invades the peritoneum, other organs, or 
adjacent structures
N — regional 
lymph nodes
comment
NX Lymph nodes have not been assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
M — distant 
metastases
comment
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
x If more than one tumour is present, we add “m” to the letter T, regardless of 
the size. xx If there is evidence of distant metastasis, the anatomical site should 
be specified in the brackets as follows: PUL for pulmonary, HEP for hepatic, and 
OSS for osseous.
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M1a Only hepatic metastases,
M1b Extra-hepatic metastases,
M1c Both hepatic and extra-hepatic metastases.
Clinical staging of NENs of the small intestine ac-
cording to ENETS is presented in Table II [4] 
A slightly less developed clinical staging according 
to AJCC/UICC 2017 is presented for comparison [71, 72] 
(Table III). 
3.3.2. Neuroendocrine neoplasms of the appendix
Pathogenesis
Most NENs of the appendix are detected during surgery 
due to acute inflammation of the organ.
Well-differentiated NENs are mostly found in 
the terminal part of the appendix (75%), less fre-
quently in the middle part (15%) and in the proxi-
mal margin (10%). Macroscopically, they form hard, 
whitish-yellow, not encapsulated nodules, with an 
expanding growth margin, whereas MiNEN tumours, 
including goblet cell carcinoid, are white, sometimes 
mucous, of 1–5 cm in diameter (mean diameter 
of 2 cm), and show an infiltrative growth pattern. 
These neoplasms are malignant; they are classified 
and treated like classical adenocarcinomas of the 
appendix [3].
3.3.2.1. Diagnostic algorithm
Contrary to the NENs of the jejunum and ileum, for 
which a similar consensus was developed regarding 
the assessment of the T-staging, two classifications are 
recommended for the NENs of the appendix: one by 
the European Neuroendocrine Tumour Society (ENETS) 
and the other by the American associations: American 
Joint Committee on Cancer/Union for International Can-
cer Control (AJCC/UICC). It is recommended that both 
classifications are used. Firstly, because presently there 
is no evidence in favour of the usefulness of either of 
them, and secondly, because in cases raising doubts as 
to the scope of therapeutic management on the basis of 
one classification, the use of the other one could resolve 
the doubts [3].
Macroscopic assessment of NENs of the appendix.
A relatively low incidence of NENs of the appendix 
should always be a reason for very careful macroscopic 
examination and careful sample collection. Procedures 
included in the Standards of the Polish Society of Pa-
thologists should be followed during the preparation 
of the post-surgical material from the removed small 
intestinal tumour [68]. The samples should be collected 
from the end of the appendix, its middle part, and 
base (the proximal colonic margin), and the size of the 
tumour should be stated.
The macroscopic description should include the 
following:
The length of the appendix obtained for examina-
tion, with a description of the tumour location relative 
to the resection margin.
 — Tumour assessment: the size in three dimensions, 
and cross-section appearance.
 — Condition of the serosa and mesoappendix at the 
tumour site — it is necessary to collect numerous 
samples.
Microscopic assessment of NENs of the appendix:
1. Histological type of NEN according to the 2017 
WHO classification [3, 69] completed with informa-
tion from Chapter 2.2 and Table VII.
2. The histological grading (G) according to ENETS 
[3, 32].
3. Assessment of immunohistochemical expression 
of neuroendocrine markers: chromogranin A and 
synaptophysin, as well the Ki-67/MIB1 prolifera-
tive activity, is obligatory. Immunohistochemical 
assessment of NSE, CD56, CDX2 markers, and 
serotonin is recommended conditionally, in the 
case of metastatic differentiation, especially if the 
original site of the neoplasm is unknown. A posi-
tive reaction with CDX2 and/or serotonin indicates 
an intestinal, particularly ileocaecal, origin of the 
neoplasm [3].
4. The ENETS [32] and AJCC/UICC [71, 72] histopatho-
logical staging regarding the T-feature of NENs of 
the appendix is presented in Table IV [32, 71, 72]. 
Table II. Small intestinal NENs staging [4]
Stage T feature N feature M feature Advancement
0 Tis N0 M0 Local neoplasm
I T1 N0 M0 Local neoplasm
IIA T2 N0 M0 Local neoplasm
IIB T3 N0 M0 Local neoplasm
IIIA T4 N0 M0 Local neoplasm
IIIB T1-T4 N1 M0 Regional neoplasm
IV T1-T4 any M1 Generalised neoplasm
Table III. AJCC/UICC 2017 staging classification for NENs 
[71, 72]
Clinical  
stage
T feature N feature M feature
Stage I T1 N0 M0
Stage II T2, T3 N0 M0
Stage III T4 Any N M0
Any T N1, N2 M0
Stage IV Any T Any N M1
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Prognostic factors for NENs of the appendix
Tumour size and infiltration of the mesoappendix are 
important risk factors of NENs of the appendix. Accor-
ding to European and American guidelines, they form 
the criteria for division into pTNM classification stages. 
According to a report by the College of American Pa-
thologists, cases in which the diameter of the tumour is 
above 1 cm and below 2 cm, where infiltration of the me-
soappendix is present, should be treated as those having 
an uncertain prognosis. Potentially benign tumours are 
smaller than 1 cm and do not invade the mesoappendix. 
It is worth emphasising that, according to the pTNM 
2010 classification, NECs of the appendix and MANECs 
composed of classical and neuroendocrine carcinoma 
components, as well as goblet-cell carcinoids, are dia-
gnosed following the criteria for classical carcinomas, 
and not those for NENs.
Apart from the above features, the histopathological 
report should include the assessment of margins: proxi-
mal, distal, mesoappendiceal, and radial, as well as the 
angioinvasion of blood vessels. It should be noted that 
it is necessary to examine the colonic proximal margin 
because invasion of the caecum/colon determines the 
treatment method. During the assessment of the slides, 
particular attention should also be paid to any small 
periserosal vessels, which could be ignored, especially 
if the samples from the periphery of the tumour were 
inadequately collected [3]. 
UICC 2017 classification system, as was the case with 
the small intestine, differentiates metastases (M1) from 
the appendix in the following manner:
M1a Only hepatic metastases,
M1b Extra-hepatic metastases,
M1c Both hepatic and extra-hepatic metastases.
Clinical advancement stage according to the same 
classification system for the appendix is almost identical 
as for the small intestine. The only difference regards 
features N1 and N2, dependant on the number and 
weight of the metastases, which are not considered 
during the assessment of lymph node metastases, but 
only the presence of N1 metastasis is reported [72].
Minimal consensus statement on pathomorphological 
examination:
 — Minimal histopathological report on NENs of the small 
intestine and the appendix should include:
• Histological type of the neoplasm according to the 
WHO classification, considering the division into well- 
-differentiated neuroendocrine neoplasms (NEN) and 
neuroendocrine carcinomas (NEC) or mixed neoplasms 
(MiNEN);
• Histological G grading referring to well-differentiated 
neoplasms (NEN G1, NEN G2);
• pTNM histopathological staging according to ENETS 
and AJCC/UICC classifications (it is important to provide 
affiliation of the classification in each case);
Table IV. pTNM classification for NENs of the appendix according to ENETS [32] and AJCC / UICC 8th edition 2017 [71, 72] 
T feature ENETS AJCC/UICC
x The tumour has not been assessed
0 No evidence of a primary tumour
T1 Tumour of the largest diameter of ≤ 1 cm invading the submucosa 
and muscularis propria
Tumour of the largest diameter 
≤ 2 cm
T2
Tumour ≤ 2 cm and/or minimally (up to 3 mm) invading the 
submucosa, muscularis propria, and/or invading the subserosa 
and/or mesoappendix
Tumour > 2 cm and < 4 cm
T3 Tumour > 2 cm and/or invading the subserosa/mesoappendix to  
a depth greater than 3 mm
Tumour of > 4 cm or tumour invading the subserosa or invading 
mesoappendix
T4 Tumour invading the serosa or adjacent organs Tumour invading the peritoneum or other adjacent organs or 
structures (except direct intramural infiltration of the adjacent 
serosa or the intestinal wall)
N feature
Nx Lymph nodes could not be assessed histopathologically
N0 No metastases in the regional lymph nodes
N1 Metastases or metastases to the regional lymph nodes
M feature
Mx Distant metastases could not be assessed histopathologically
M0 No distant metastases
M1 Metastases or distant metastases
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• Assessment of surgical margins.
 — The histopathological diagnosis of NEN must be confirmed 
by immunohistochemical tests assessing expression of the 
neuroendocrine markers: synaptophysin and chromogra-
nin A, as well as Ki-67 proliferative activity using the 
MIB1 antigen. 
4. Treatment 
4.1. Surgical treatment
NENs of the midgut are usually located in the distal 
part of the small intestine or in the appendix. They 
frequently present in a multi-focal form, with concur-
rent hepatic metastases [3, 73]. The preferred treatment 
of intestinal NENs is partial or multiple resection with 
lymphadenectomy, as a radical treatment, or palliative, 
cytoreductive surgery reducing the tumour mass by ap-
proximately 90% [3]. If possible, the primary tumour site 
should be removed, even if the disease is generalised, 
with concurrent resection or enucleation of the hepatic 
metastatic lesions [74]. 
Treatment of aNENs depends primarily on the 
tumour size and the intensity of infiltration of the pri-
mary tumour [75–77]. The indications for right-sided 
hemicolectomy are the following tumour features:
1. Diameter of more than 2 cm, aNEN G1/G2 (NET 
classified as at least T3 (ENETS) or T2 (UICC/AJCC) 
[5, 13, 78–82];
2. Location at the base of the appendix (although 
there is no evidence for a poorer prognosis, and 
in such cases a higher incidence of complications 
should always be considered, compared to simple 
appendectomy) [79, 83–86];
3. Mesoappendiceal invasion, MAI (there is no evi-
dence of a correlation between the tumour size and 
MAI, which questions the ENETS arbitrary infiltra-
tion depth of 3 mm as a border between T2 < 3 mm 
and T3 > 3 mm) [5];
Figure 1. Algorithm of therapeutic management and monitoring of neuroendocrine tumours of the appendix found accidentally 
during appendectomy due to acute appendicitis or another gynaecological or surgical procedure in the abdominal cavity [75] 
aNENs — neuroendocrine neoplasm of the appendix; MAI — mesoappendiceal infiltration; MRI — magnetic resonance; NEN — 
neuroendocrine neoplasm; SRI — somatostatin receptor imaging; US — ultrasonography
*Performance of SRI depends on the experience and choice of the treating centre; there is no evidence of the effectiveness or necessity for this diagnostic management
**Patients who cannot be operated on due to concurrent diseases, or who do not give consent to a surgical treatment
> 1 cm Tumour < 2 cm in the presence 
of at least one risk factor:
Location at the base of the appendix, 
MAI, Ki-67 > 2%, angio- or neuroinvasion, operation R1
Abdominal CT/MRI 
every year, for 5 years
Incomplete surgery 
in histopathological examination
aNEN found accidentally following appendectomy
Localised disease
BASIC EXAMINATIONS
Physical examination, CgA, 
CT/MRI, SRI to be considered
Tumour > 2 cm
None of the above At least one of the above
SURGICAL TREATMENT 
COMPLETED
RIGHT-SIDED HEMICOLECTOMY 
TO BE CONSIDERED
PATIENTS AT HIGH SURGICAL RISK 
OR NOT GIVING CONSENT
Complete surgery 
— tumour removed completely
TREATMENT AS FOR SMALL INTESTINAL NENs
LOW RISK OF RECURRENCE
PATIENT FOLLOW-UP ACCORDING TO THE ATTENDING PHYSICIAN, considering the risk of a synchronous 
or metachronous cancer of the large intestine in patients with aNENs
Tumour < 1 cm
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4. Presence in the R1 resection margin, inability to 
assess the completeness of tumour resection, or 
doubts as to the completeness of tumour resection 
[5, 80, 81, 86];
5. G2 feature according to WHO [87];
6. V1 neuro- and angioinvasion, L1 infiltration of 
lymph nodes — increase the risk of metastases to 
the lymph nodes [82];
7. Goblet cell carcinoid, MiNEN and NEC G3 are not 
classified as NEN; they should be treated according 
to the recommendations regarding adenocarcinoma 
[5, 32, 71, 76];
8. In NENs of the appendix with hepatic metas-
tases, the recommended management is right- 
-sided hemicolectomy including removal of the 
metastases (anatomical and non-anatomical resec-
tions) [74].
In the case of multiple metastases, a palliative sur-
gery removing the metastases should be considered 
(resection, thermoablation, chemoembolisation) [5, 
32] (Fig. 1). 
Minimal consensus statement on surgical treatment:
 — Surgical treatment of the midgut tumours involves the 
complete removal of the tumour within the healthy tis-
sue, together with the lymph nodes (*evidence level 3).
 — In palliative treatment, cytoreductive management should 
be considered (*evidence level 3).
 — In tumours of the appendix of < 2 cm, without any risk 
factors, appendectomy should be performed.
 — In tumours of > 2 cm and more advanced tumours, right-
sided hemicolectomy should be performed (*evidence level 3). 
4.2. Symptomatic pharmacological treatment
4.2.1. Symptomatic treatment in carcinoid syndrome
 — Long-acting somatostatin analogues: octreotide LAR 
(10–30 mg i.m. every four weeks, but the lowest 
dose is rarely used), lanreotide Autogel (60–120 mg 
s.c. every 4–6 weeks, but the lowest dose is rarely 
used) are the gold standards in the treatment of 
carcinoid syndrome (see p. 79–110) [88, 89, 90, 91]. 
Radioisotope imaging of somatostatin receptors is 
not required before the SSA treatment.
 — If the symptom control is not satisfactory during 
standard treatment with long-acting somatostatin 
analogues, the following should be considered: 
reducing the interval between injections, increas-
ing the dose of SSA, and/or adding a short-acting 
SSA (octreotide, solution for injections 100 μg/amp).
 — In the case of resistance to SSA, in some patients 
a new SSA (pasireotide) is found to be effective [92]. 
Moreover, a new drug inhibiting the biosynthesis 
of serotonin, telotristat (LX1032), is presently being 
studied in clinical trials in patients with carcinoid 
syndrome [93, 94].
 — The symptomatic treatment of patients with carci-
noid syndrome also involves loperamide, ondanse-
tron, and pancreatic enzymes, or group B vitamins 
in case of deficiency [23]. 
 — Patients with carcinoid heart disease require care 
in referential cardiological and cardiosurgical 
centres [27]  
4.2.2. Carcinoid crisis treatment
 — There are no clear EBM recommendations for the 
management of carcinoid crisis [3].
 — The soonest possible introduction of somatostatin 
analogue therapy is of the greatest importance; 
a short-acting SSA in high doses is usually admin-
istered intravenously (octreotide: 25–500 µg/h IV; 
on average 100–200 µg/h IV) [30]. In carcinoid crisis 
(particularly in NENs of the foregut), the administra-
tion of glucocorticoids and antihistamines may be 
considered.
 — It is necessary to introduce intensive symptomatic 
treatment of dehydration, acute renal failure, hy-
percalcaemia, arterial hypertension or hypotonia, 
cardiac failure, and infection [3]. 
4.2.3. Preparation of patients with NETs of the small 
intestine and the appendix for surgery
 — There are no clear recommendations for the prepa-
ration of patients with NENs of the small intestine 
and appendix for surgery [95].
 — In patients with carcinoid syndrome, pre-oper-
ative administration of short-acting SSA should 
be considered, regardless of the long-acting 
SSA therapy (e.g. octreotide 200–300 µg s.c. be-
fore the surgery and/or continuous infusion of 
50–100 µg/hour intraoperatively and/or 24–48 hours 
after the surgery) [3]. Cardiological consultation 
should be considered before the surgery. 
 — In patients with hormonally non-active NENs, it 
is recommended that a short-acting SSA should be 
available during the operation, and administered 
in the case of an unstable haemodynamic condi-
tion [3]. 
4.3. Systemic treatment of small intestinal NENs 
in the generalised period
4.3.1. Long-acting somatostatin analogues
 — Long-acting somatostatin analogues: octreotide 
LAR (30 mg i.m. every four weeks), lanreotide 
Autogel (120 mg s.c. every four weeks) are first-line 
therapies to stabilise neoplastic disease in patients 
*evidence level according to OCEBM [109]
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with well-differentiated NETs of the small intestine 
in the generalised period (see p. 79–110) [96, 97].
4.3.2. Peptide Receptor Radionuclide Therapy 
with radioisotope-labelled somatostatin analogues 
(PRRT)
 — In patients with metastatic NETs of the small 
intestine with a high expression of somatostatin 
receptors, in progression during the SSA treatment, 
therapy with radioisotope-labelled somatostatin 
analogues should be considered as the first-line 
treatment [98]. Qualification and treatment should 
follow the principles described in "Diagnostic and 
therapeutic guidelines for gastro-entero-pancreatic 
neuroendocrine neoplasms" (p. 79–110).
 — In patients with negative receptor scintigraphy and 
evidence of 131I-MIBG accumulation in the tumour 
or metastases, therapy with 131I-MIBG may be con-
sidered [99]. 
4.3.3. Targeted therapies — everolimus
Everolimus therapy is effective in patients with hor-
monally non-active, well-differentiated gastro-entero-
pancreatic NETs, including small intestinal NETs, in the 
generalised period [100]. Everolimus may be consid-
ered in patients with generalised progressing NETs of 
the small intestine following ineffective SSA treatment, 
and when other treatment methods (including PRRT) 
are ineffective or cannot be applied. In Poland everoli-
mus therapy for this indication is non-refundable. 
4.3.4. Chemotherapy
Due to limited effectiveness, chemotherapy is not recom-
mended as the first-line treatment in patients with well-
differentiated, metastatic neuroendocrine tumours of the 
small intestine. It is used exclusively in advanced small 
intestinal NETs, when other treatment methods appear 
ineffective. CAPTEM (temozolomide + capecitabine) may 
be considered, on the basis of small, prospective, phase II 
studies involving small groups of patients [101–103]. The 
principles of chemotherapy have been described in "Di-
agnostic and therapeutic guidelines for gastro-entero-
pancreatic neuroendocrine neoplasms" (p. 79–110). 
Goblet cell carcinoma (GCC)
Goblet cell carcinoids of the appendix constitute 
a specific form of neuroendocrine neoplasms of the ap-
pendix. These rare and aggressive neoplasms comprise 
both glandular and neuroendocrine components, and 
their course is aggressive [104, 105]. 
Adjuvant chemotherapy – qualification according to 
the same principles as in cancer of the large intestine: 
FOLFOX is recommended in stage III (pT3, pT4, N+), 
although there are no reports from randomised studies, 
only scientific reports from individual centres [5, 106].
In the case of a diffused neoplasm, or recurrence 
after a radical treatment, due to a similar course of dis-
ease to glandular cancer of the large intestine, the same 
chemotherapy regimens are recommended (FOLFOX, 
FOLFIRI). Hyperthermic intraperitoneal chemoperfu-
sion using mitomycin (HIPEC) and systemic chemo-
therapy, as well as surgical cytoreduction, may improve 
the prognosis in patients with diffused or recurrent 
GCC in the peritoneum [107, 108].
Minimal consensus statement on pharmacological and 
radioisotope treatment of NENs of the small intestine 
and the appendix 
Long-acting SSA are the treatment of choice in case of 
hormonally active small intestinal NETs (carcinoid syndrome 
and carcinoid crisis) (evidence level 1) [109].
In the case of small intestinal NETs in the generalised 
period (hormonally active and non-active), long-acting SSA 
should be used (antiproliferative effect) (*evidence level 1).
In patients with generalised NENs of the small intestine 
in progression during the SSA treatment, and with a good 
expression of somatostatin receptors, radioisotope therapy 
should be the first-line treatment (*evidence level 1), and 
targeted therapies should be considered afterwards — everoli-
mus (*evidence level 1). In patients with a low expression of 
somatostatin receptors, targeted therapy is indicated.
When the above therapies are exhausted, in certain cases 
chemotherapy may be considered (*evidence level 4). 
5. Monitoring 
Determination of CgA and 5-HIAA may be useful for 
the assessment of treatment and its effectiveness in 
patients with carcinoid symptoms. In patients treated 
with SSA, lower excretion of 5-HIAA and decreased 
levels of chromogranin A are associated with reduced 
intensity and frequency of clinical symptoms (flush-
ing, diarrhoea). However, it is believed that 5-HIAA 
excretion does not reflect the progression or the re-
sponse to treatment as precisely as the monitoring of 
CgA concentration. A high association (80%) between 
changes in the tumour size and concentration of 
chromogranin A has been observed. An even higher 
association (88%) was found in a group of patients 
with non-secreting tumours, in whom other markers 
could not be used [2, 3, 34]. However, in certain pa-
tients a very good clinical response to the treatment of 
carcinoid syndrome with SSA was observed, without 
reduced CgA levels [3].
The frequency of follow-up examinations depends 
on NEN differentiation and staging, as well as on the 
introduced treatment (see p. 79–110). The physical 
*evidence level according to OCEBM [109]
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examination and additional tests (three-phase CT scan-
ning of the abdominal cavity and radioisotope imaging 
of somatostatin receptors SRI), as well as biochemical 
indicators (CgA and 5-HIAA), should be monitored. 
After a radical surgery: in patients with NET G1 and 
G2 every 6–12 months. In the case of a residual tumour 
or metastases: in patients with NET G1-G2, every 3–6 
months. In G3, NEC: every 2–3 months [110].
In patients with carcinoid heart disease, echocar-
diographic examination and NT-proBNP assessment 
should be repeated at least every 12 months. If the 
disease progresses, follow-up imaging and biochemical 
tests need to be conducted more frequently — every 
three months [38, 110].
Minimal consensus statement on follow-up:
Monitoring of the disease and treatment should be planned 
individually for each patient, considering the clinical picture, 
grading, and staging of the disease, and its treatment.
In well-differentiated aNETs with a maximum tumour 
size < 1 cm and resection status (R0), further follow-up is 
not required. Patients with NET-G1 should be assessed every 
6–12 months, with NET-G2, every 3–6 months, and with 
NEN-G3, every 3 months.
minimal examination includes: CgA, 5-HIAA (in certain 
cases) and triphasic CT, as well as radioisotopes somato-
statin receptor imaging (SRI);
echocardiographic examination and NT-proBNP every 
6–12 months in patients with carcinoid heart disease. 
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